<DOC>
	<DOCNO>NCT01228942</DOCNO>
	<brief_summary>The purpose study determine COXEN algorithm , use diagnostic device Affymetrix GeneChip , able predict chemotherapy best treatment recurrent persistent ovarian , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>A Prospective Trial COXEN Chemotherapy Prediction</brief_title>
	<detailed_description>The current proposal seek apply extend novel genomic prediction technique find well chemotherapeutic option recurrent ovarian cancer use individual patient ' gene-expression signature chemosensitivity . The utility COXEN technique validate found accurately predict 1 ) chemosensitivity independent panel 40 bladder cancer cell line ; 2 ) activity &gt; 45K candidate compound NCI-60 drug screen database , result identification highly-effective novel compound bladder cancer patient ' response survival 12 historical clinical trial combination chemotherapy . In particular , GEMs breast cancer use stratify clinical response overall patient survival strike difference predict responder vs. predict non-responders 5 independent chemotherapeutic trial breast cancer . The next step test prediction model recurrent ovarian cancer .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<criteria>age great 18 diagnosis recurrent , persistent , refractory ovarian , fallopian primary peritoneal cancer tumor tissue , ascites pleural fluid available biopsy life expectancy great 6 month patient borderline low malignant histology patient history malignancy within last 5 year</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cancer</keyword>
</DOC>